Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Cosentyx (secukinumab) is a biologic that inhibits interleukin-17A, a cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and axial spondyloarthritis. Now it is approved for hidradenitis suppurativa.
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Novartis Cosentyx® as The First New Biologic Treatment Option for Hidradenitis Suppu...
Details : Cosentyx (secukinumab) is a biologic that inhibits interleukin-17A, a cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and axial spondyloarthritis. Now it is approved for hidradenit...
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
October 31, 2023
Details:
Cosentyx (secukinumab) is an interleukin-17A (IL-17A) inhibitor, previously approved for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis & axial spondyloarthritis. It is now approved for hidradenitis suppurativa.
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Novartis Cosentyx® as the First New Biologic Treatment Option for Hidradenitis Suppu...
Details : Cosentyx (secukinumab) is an interleukin-17A (IL-17A) inhibitor, previously approved for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis & axial spondyloarthritis. It is now approved for hidradenitis suppurativa.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
October 31, 2023
Details:
Cosentyx (secukinumab) is an intravenous formulation that specifically targets and blocks interleukin-17A (IL-17A), which is indicated for the treatment of rheumatic diseases.
Lead Product(s): Secukinumab
Therapeutic Area: Immunology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Novartis Cosentyx® as First Intravenous (IV) Formulation Interleukin-17A Antagonist ...
Details : Cosentyx (secukinumab) is an intravenous formulation that specifically targets and blocks interleukin-17A (IL-17A), which is indicated for the treatment of rheumatic diseases.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2023
Details:
Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis.
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 26, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Cosentyx® Gains Positive CHMP Opinion for Hidradenitis Suppurativa
Details : Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
April 26, 2023
Details:
Cosentyx (secukinumab) is the human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 02, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cosentyx (secukinumab) is the human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyl...
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
April 02, 2023
Details:
Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A and received European approval for for hidradenitis suppurativa.
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A and received European approval for for hidradenitis suppurativa.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
January 06, 2023
Details:
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms.
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Brand Name: Cosentyx
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2022
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Cosentyx® Shows Clinically Meaningful Symptom Improvements in Patients With Hidradenitis...
Details : Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
September 09, 2022
Details:
Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).
Lead Product(s): Secukinumab
Therapeutic Area: Immunology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2022
Lead Product(s) : Secukinumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosentyx® (Secukinumab) Receives Expanded Approvals in EU for Use in Childhood Arthritic Conditio...
Details : Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with enthesitis-related arthritis (ERA) and psoriatic arthritis ...
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
June 27, 2022
Details:
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU.
Lead Product(s): Secukinumab,Methotrexate
Therapeutic Area: Immunology Brand Name: Cosentyx
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2022
Lead Product(s) : Secukinumab,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
May 20, 2022
Details:
Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress.
Lead Product(s): Secukinumab
Therapeutic Area: Immunology Brand Name: Cosentyx
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 09, 2022
Lead Product(s) : Secukinumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
February 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Solubilizers
Parenteral
Topical
Emulsifying Agents
Thickeners and Stabilizers
Film Formers & Plasticizers
Surfactant & Foaming Agents
Co-Processed Excipients
Taste Masking
Direct Compression
Rheology Modifiers
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
